The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions

Multiple genetic loci confer susceptibility to breast and ovarian cancers. We have previously developed a model (BOADICEA) under which susceptibility to breast cancer is explained by mutations in BRCA1 and BRCA2, as well as by the joint multiplicative effects of many genes (polygenic component). We have now updated BOADICEA using additional family data from two UK population-based studies of breast cancer and family data from BRCA1 and BRCA2 carriers identified by 22 population-based studies of breast or ovarian cancer. The combined data set includes 2785 families (301 BRCA1 positive and 236 BRCA2 positive). Incidences were smoothed using locally weighted regression techniques to avoid large variations between adjacent intervals. A birth cohort effect on the cancer risks was implemented, whereby each individual was assumed to develop cancer according to calendar period-specific incidences. The fitted model predicts that the average breast cancer risks in carriers increase in more recent birth cohorts. For example, the average cumulative breast cancer risk to age 70 years among BRCA1 carriers is 50% for women born in 1920–1929 and 58% among women born after 1950. The model was further extended to take into account the risks of male breast, prostate and pancreatic cancer, and to allow for the risk of multiple cancers. BOADICEA can be used to predict carrier probabilities and cancer risks to individuals with any family history, and has been implemented in a user-friendly Web-based program (http://www.srl.cam.ac.uk/genepi/boadicea/boadicea_home.html).

[1]  Giovanni Parmigiani,et al.  Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. , 2007, Journal of the National Cancer Institute.

[2]  C. Begg.  On the use of familial aggregation in population-based case probands for calculating penetrance. , 2002, Journal of the National Cancer Institute.

[3]  J. Eyfjörd,et al.  Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920-2000. , 2006, Journal of the National Cancer Institute.

[4]  P. Pharoah,et al.  Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases , 2000, British Journal of Cancer.

[5]  S. Seal,et al.  Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. , 1999, Journal of the National Cancer Institute.

[6]  S. Seal,et al.  PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene , 2007, Nature Genetics.

[7]  Jaana M. Hartikainen,et al.  A common coding variant in CASP8 is associated with breast cancer risk , 2007, Nature Genetics.

[8]  S. Seal,et al.  A genome wide linkage search for breast cancer susceptibility genes , 2006, Genes, chromosomes & cancer.

[9]  H. Akaike.  A new look at the statistical model identification , 1974 .

[10]  R. Goldbohm,et al.  Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease , 2001, The Lancet.

[11]  Dieter Niederacher,et al.  Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. , 2008, American journal of human genetics.

[12]  Thorunn Rafnar,et al.  Prostate cancer progression and survival in BRCA2 mutation carriers. , 2007, Journal of the National Cancer Institute.

[13]  Nazneen Rahman,et al.  CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. , 2004, American journal of human genetics.

[14]  T. Rebbeck,et al.  Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. , 2002, Journal of the National Cancer Institute.

[15]  G. Mills,et al.  Assessing BRCA carrier probabilities in extended families. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Douglas F Easton,et al.  BRCA1 and BRCA2 mutations in a population-based study of male breast cancer , 2001, Breast Cancer Research.

[17]  D. Easton,et al.  The BOADICEA model of genetic susceptibility to breast and ovarian cancer , 2004, British Journal of Cancer.

[18]  Peter Kraft,et al.  Heterogeneity of Breast Cancer Associations with Five Susceptibility Loci by Clinical and Pathological Characteristics , 2008, PLoS genetics.

[19]  C B Begg,et al.  The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[20]  N E Day,et al.  A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes , 2002, British Journal of Cancer.

[21]  H. Olsson.  Cancer risks in BRCA2 mutation carriers. , 1999, Journal of the National Cancer Institute.

[22]  J. Ferlay,et al.  Cancer Incidence in Five Continents , 1970, Union Internationale Contre Le Cancer / International Union against Cancer.

[23]  D. Gudbjartsson,et al.  Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor–positive breast cancer , 2007, Nature Genetics.

[24]  Nazneen Rahman,et al.  ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles , 2006, Nature Genetics.

[25]  Anglian Breast Cancer Study Group.  Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases , 2000 .

[26]  R. Barkardottir,et al.  The effect of a single BRCA2 mutation on cancer in Iceland , 2002, Journal of medical genetics.

[27]  Barry Rosen,et al.  Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. , 2006, Journal of the National Cancer Institute.

[28]  C. Begg,et al.  Variation of breast cancer risk among BRCA1/2 carriers. , 2008, JAMA.

[29]  Nazneen Rahman,et al.  Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles , 2006, Nature Genetics.

[30]  D. Berry,et al.  Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. , 1998, American journal of human genetics.

[31]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[32]  D. Schaid.  Mathematical and Statistical Methods for Genetic Analysis , 1999 .

[33]  Douglas F Easton,et al.  Cancer Incidence in BRCA1 mutation carriers. , 2002, Journal of the National Cancer Institute.

[34]  H O Dickinson,et al.  Cancer trends in England and Wales , 2000, BMJ : British Medical Journal.

[35]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.

[36]  D. Easton,et al.  BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families , 2005, Breast Cancer Research.

[37]  P. Pharoah,et al.  Prediction of pathogenic mutations in patients with early-onset breast cancer by family history , 2003, The Lancet.

[38]  John L Hopper,et al.  Familial risks, early-onset breast cancer, and BRCA1 and BRCA2 germline mutations. , 2003, Journal of the National Cancer Institute.

[39]  J. Eyfjörd,et al.  Study of a single BRCA2 mutation with high carrier frequency in a small population. , 1997, American journal of human genetics.

[40]  N E Day,et al.  Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population‐based study , 2001, Genetic epidemiology.

[41]  Lester L. Peters,et al.  Genome-wide association study identifies novel breast cancer susceptibility loci , 2007, Nature.

[42]  J. C. Houwelingen,et al.  Cancer risks in BRCA2 families: estimates for sites other than breast and ovary , 2005, Journal of Medical Genetics.

[43]  D. Easton,et al.  Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. , 2001, American journal of human genetics.

[44]  K. Offit,et al.  BRCA Mutations and Risk of Prostate Cancer in Ashkenazi Jews , 2004, Clinical Cancer Research.

[45]  C. Plass,et al.  20q11.1 amplification in giant‐cell tumor of bone: Array CGH, FISH, and association with outcome , 2006, Genes, chromosomes & cancer.

[46]  B. Ponder,et al.  Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. , 2003, American journal of human genetics.

[47]  R. Eeles,et al.  Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics , 2008, Journal of Medical Genetics.

[48]  D. Easton.  How many more breast cancer predisposition genes are there? , 1999, Breast Cancer Research.

[49]  W. Willett,et al.  A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer , 2007, Nature Genetics.

[50]  Stephen W Duffy,et al.  A breast cancer prediction model incorporating familial and personal risk factors , 2004, Hereditary Cancer in Clinical Practice.

[51]  Lesley McGuffog,et al.  Cancer risks and mortality in heterozygous ATM mutation carriers. , 2005, Journal of the National Cancer Institute.